Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 10/20 | 0.55 |
| ▸ | SELP | P16109 | 2/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.37 |
| ▸ | MAG | P20916 | 5/20 | 0.37 |
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13574211 | 0.86 | SELE (0.66) | SELESELP | |
| SCHEMBL15214250 | 0.85 | SELE (0.74) | SELESELP | |
| SCHEMBL12420062 | 0.84 | SELE (0.48) | SELESELPSELLMAGSIGLEC7 | |
| SCHEMBL15434868 | 0.83 | SELE (0.42) | SELESELPSELLMAG | |
| SCHEMBL19559699 | 0.82 | SELE (0.46) | SELESELPSELLMAGSIGLEC7 | |
| SCHEMBL15434864 | 0.82 | SELE (0.42) | SELESELPSELLMAG | |
| SCHEMBL15434865 | 0.82 | SELE (0.41) | SELESELPSELLMAGSIGLEC7 | |
| SCHEMBL12216748 | 0.82 | SELE (0.69) | SELESELP | |
| SCHEMBL12421186 | 0.81 | SELE (0.50) | SELESELPSELLMAGSIGLEC7 | |
| SCHEMBL15434869 | 0.81 | SELE (0.41) | SELESELPSELLMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885SELL 4/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885SELL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.